Claritas Rx Offers Four Strategies to Mitigate Specialty Treatment Abandonment
Claritas Rx Offers Four Strategies to Mitigate Specialty Treatment Abandonment
New White Paper Entitled “From Prescription to Abandonment: How 31% of Specialty Medications Go Unfilled Across Therapeutic Areas” Now Available
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Claritas Rx, the leader in technology and analytics to optimize the specialty patient experience, announces the availability of its new white paper entitled “From Prescription to Abandonment: How 31% of Specialty Medications Go Unfilled Across Therapeutic Areas.” The new thought piece explores patient abandonment during pharmacy transitions and contributing factors of abandonment including administrative complexity, communications failures, insurance and cost concerns, and patient burden.
“Specialty medications often require complex handling, prior authorization, and patient education, making continuity of care essential to maintaining quality of life,” said Hillary Gretton, Director of Data Strategy at Claritas Rx.
Share
“Specialty medications often require complex handling, prior authorization, and patient education, making continuity of care essential to maintaining quality of life,” said Hillary Gretton, Director of Data Strategy at Claritas Rx. “However, as patients transition between specialty pharmacies, care can be disrupted due to various causes, such as payer mandates, changes in benefit design, or provider transitions.”
The paper discusses various stakeholder perspectives and analysis on over 85,000 de-identified specialty prescriptions assessing how pharmacy transfers and ownership type impact prescription fulfillment (fill rates). It also reveals the four strategies to mitigate specialty patient treatment abandonment:
- Proactive patient communications and cross-stakeholder coordination
- Leveraging technology and workflow automation
- Distribution channel partner evaluations and “scorecarding”
- Patient navigation support
“With the right strategies, including proactive outreach, data-driven insights, and tech-enabled coordination, stakeholders can reduce abandonment and improve outcomes for patients on specialty therapies,” said Ms. Gretton.
In addition to Ms. Gretton, Vaibhav Chaudhari, Data Scientist at Claritas Rx and Stuart Kamin, SVP of Analytics and Innovation at Claritas Rx also contributed to the white paper.
Media can request a copy of the paper by contacting Elizabeth Marshall at EMarshall@ClaritasRx.com.
About Claritas Rx
Based in South San Francisco, CA, Claritas Rx is a technology company focused on managing real world data focused on specialty biopharmaceutical distribution channels in oncology and rare/orphan diseases. Since 2011, the company has illuminated brand performance and the patient journey for dozens of therapies. Claritas Rx creates actionable business intelligence that helps manufacturers more effectively go to market and enhance the patient experience. For more information, visit www.claritasrx.com.
Contacts
Media Contact: Elizabeth Marshall, EMarshall@ClaritasRx.com
